In the view of the analysts at Goldman Sachs, USD/JPY is likely to drop amid a rebound expected in the yen and Fed rate hike bets pushed back.
“In the medium-term USD/JPY may rise, due to boosts from the vaccine surge in growth and inflation.”
“But then heads lower as aggressive Fed hike bets are cut back ...”
"We expect no hikes until 2024, whereas markets price about three hikes before then.0"
"In the second half of 2021, when we will be on the other side of the vaccine-led surge in US activity, and when Japan's own vaccination campaign should be catching up, we expect USD/JPY to turn lower again."
“Speculative yen shorts have accumulated despite the lack of evidence of Japanese foreign bond purchases accelerating.”
“A swing from longs to shorts in Q1 likely helped yen depreciation and this pressure on the currency is likely gone.”
“The yen is cheap relative to longer-term valuation.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.